Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-748-5975
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.35 million
Profitability
Miscellaneous
Employees115
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions
What is Dova Pharmaceuticals' stock symbol?
Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."
How were Dova Pharmaceuticals' earnings last quarter?
Dova Pharmaceuticals Inc (NASDAQ:DOVA) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.60) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.03. The firm had revenue of $3.52 million for the quarter, compared to analysts' expectations of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. View Dova Pharmaceuticals' Earnings History.
When is Dova Pharmaceuticals' next earnings date?
What price target have analysts set for DOVA?
6 brokers have issued 12 month target prices for Dova Pharmaceuticals' stock. Their predictions range from $15.00 to $30.00. On average, they anticipate Dova Pharmaceuticals' stock price to reach $26.42 in the next year. This suggests that the stock has a possible downside of 5.9%. View Analyst Price Targets for Dova Pharmaceuticals.
What is the consensus analysts' recommendation for Dova Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals.
Has Dova Pharmaceuticals been receiving favorable news coverage?
Media stories about DOVA stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Dova Pharmaceuticals earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Dova Pharmaceuticals.
Are investors shorting Dova Pharmaceuticals?
Dova Pharmaceuticals saw a drop in short interest in the month of September. As of September 15th, there was short interest totalling 1,770,000 shares, a drop of 16.9% from the August 15th total of 2,130,000 shares. Based on an average daily trading volume, of 419,500 shares, the days-to-cover ratio is presently 4.2 days. Currently, 13.6% of the shares of the company are short sold. View Dova Pharmaceuticals' Current Options Chain.
Who are some of Dova Pharmaceuticals' key competitors?
Some companies that are related to Dova Pharmaceuticals include Allakos (ALLK), Nektar Therapeutics (NKTR), Mirati Therapeutics (MRTX), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), Emergent Biosolutions (EBS), Alkermes (ALKS), Genmab A/S (GMAB), Myokardia (MYOK), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT) and Ra Pharmaceuticals (RARX).
What other stocks do shareholders of Dova Pharmaceuticals own?
Who are Dova Pharmaceuticals' key executives?
Dova Pharmaceuticals' management team includes the folowing people:
- Dr. David S. Zaccardelli, Pres & CEO (Age 54)
- Mr. Mark W. Hahn, CFO & Sec. (Age 56)
- Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)
- Mr. Jason Levine, VP of Marketing
- Mr. Ilija Zlatar, Head of U.S. Sales
When did Dova Pharmaceuticals IPO?
(DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.
Who are Dova Pharmaceuticals' major shareholders?
Dova Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Meeder Asset Management Inc. (0.00%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Mark W Hahn, Paul B Manning, Roger Jeffs and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.
Which major investors are buying Dova Pharmaceuticals stock?
DOVA stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, David Zaccardelli, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.
How do I buy shares of Dova Pharmaceuticals?
Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Dova Pharmaceuticals' stock price today?
One share of DOVA stock can currently be purchased for approximately $28.07.
How big of a company is Dova Pharmaceuticals?
Dova Pharmaceuticals has a market capitalization of $808.42 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.
What is Dova Pharmaceuticals' official website?
How can I contact Dova Pharmaceuticals?
Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]
MarketBeat Community Rating for Dova Pharmaceuticals (NASDAQ DOVA)
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
